ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended														12 Months Ended												12 Months Ended				12 Months Ended				12 Months Ended					12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 Abilify [Member]	Dec. 31, 2011 Abilify [Member]	Dec. 31, 2010 Abilify [Member]	Dec. 31, 2012 Otsuka [Member] Abilify [Member]	Dec. 31, 2011 Otsuka [Member] Abilify [Member]	Dec. 31, 2010 Otsuka [Member] Abilify [Member]	Dec. 31, 2012 Otsuka [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 1999 Otsuka [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 Otsuka [Member] Abilify, Sprycel and Ixempra [Member]	Dec. 31, 2011 Otsuka [Member] Abilify, Sprycel and Ixempra [Member]	Dec. 31, 2010 Otsuka [Member] Abilify, Sprycel and Ixempra [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales up to 2 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales over 4 Point 2 billion [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Apr. 30, 2009 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 Otsuka [Member] France, Germany, Spain, and United Kingdom [Member] Abilify [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2010 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Operating expense up to $175 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Operating expenses over $175 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales over $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales over $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales up to 2 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales over 4 Point 2 billion [Member]
Alliances and Collaborations Statement [Line Items]
Percentage of net sales recognized from collaboration																										51.50%	53.50%	58.00%	50.00%	20.00%	7.00%	2.00%	1.00%	20.00%								65.00%
Percentage of operating expense reimbursements from collaboration																										30.00%																				20.00%	1.00%
Payment to extend term of commercialization agreement																																						$ 400
Total upfront, milestone and other licensing payments																					60
Percentage of net sales payable to collaboration partner																										1.50%																						30.00%	65.00%	5.00%	12.00%	3.00%	3.00%	2.00%	2.00%	1.00%	1.00%
Range of sales at which a given percentage will be paid to collaboration partner - maximum																																																400		600		800		1,000				2,700	3,200	3,700	4,000	4,200
Range of sales at which a given percentage will be paid to collaboration partner - minimum																																																		400		600		800		1,000			2,700	3,200	3,700	4,000	4,200
Amount of operating expense at or below which collaboration partner will reimburse given percentage																																														175
Amount of operating expense over which collaboration partner will reimburse given percentage																																															175
Abilify* net sales, including amortization of extension payment	4,191	3,736	4,443	5,251	5,454	5,345	5,434	5,011				17,621	21,244	19,484	2,827	2,758	2,565	2,827	2,758	2,565
Oncology Products collaboration fee expense																																											138	134	128
Royalty expense																		78	72	62
Reimbursement of operating expenses to/(from) Otsuka																							(49)	(47)	(101)
Amortization (income)/expense - extension payment																																			66	66	66
Amortization expense - upfront, milestone and other licensing payments												607	353	271																									5	6	6
Other assets - extension payment	904				824							904	824																						153	219
Other intangible assets - upfront, milestone and other licensing payments	8,778				3,124							8,778	3,124																											5
Total upfront, milestone and other licensing payments expensed to IPRD																						157
Total capitalized and expensed upfront, milestone and other licensing payments																					217
Payment made to Otsuka to assume full responsibility for providing and funding all sales force efforts																										27
Maximum reimbursement of operating expenses payable to a collaboration partner									$ 8	$ 56	$ 82